Definitive Contract 75F40121C00199
Award Date
9/30/21
Potential Completion Date
3/30/25
Potential Value
$2.4M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
B537 - Special Studies/Analysis- Medical/Health
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20903, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization specializing in early phase drug development services. The $1,293,840.24 firm fixed price definitive contract is for a project on the pharmacokinetics study of an opioid drug product following insufflation of milled drug products. The contract has an ultimate completion date of September 30, 2019 and was awarded on September 17, 2015. No...
This is a federal contract award from the National Institute on Drug Abuse (NIDA), a civilian agency, to Altasciences Clinical Kansas Inc., a for-profit contract research organization (CRO). The $1,340,461.88 firm fixed-price delivery order is for a clinical trial to assess the safety, tolerability, and pharmacokinetics of an investigational agent for substance use disorder (SUD) treatment. The contract is part of NIDA's $21 million indefinite delivery contract N01DA-23-8935, which supports...
This is a $3,562,513 cost-plus-fixed-fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc. The contract is for pharmacokinetic and pharmacodynamic studies to support the development of medications for substance use disorders. The contract period of performance is from September 20, 2017 to September 19, 2022, with an ultimate completion date of July 31, 2025. This award is not associated...
This is a $983,066 firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization, to conduct a bioequivalence study of lamotrigine extended release tablets. The delivery order was issued against an existing $21 million single-award indefinite delivery contract with the National Institute on Drug Abuse (NIDA) for pharmacokinetic and pharmacodynamic trials to develop medications for substance use...
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $134,500 firm fixed price purchase order to Xenobiotic Laboratories Inc. Biotesting Division for assessment of inhibition activity and substrate potential of two test articles for major human drug transporters. The solicitation requested the prime contractor evaluate Mitragynine and its metabolite 7-hydroxymitragynine to support drug development, using study...
This is a firm fixed price delivery order awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc., a contract research organization. The $1,838,615.00 delivery order is for Altasciences to conduct Phase 1 cocaine drug interaction trials from September 2023 through March 2025 in Overland Park, Kansas. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $1,436,776 firm fixed price delivery order to Altasciences Clinical Kansas Inc. to conduct a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of an investigational agent from September 3, 2024 to March 2, 2026. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for pharmacokinetic and pharmacodynamic...
This is a delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the U.S. Department of Health and Human Services. The contract, valued at $2,373,515.00, is for non-clinical safety evaluations of mitragynine to support its future development as an oral analgesic (pain relief) therapy. The prime contractor is the IIT Research Institute (IITRI), a non-profit contract research organization and division of the Illinois Institute of...
Xenobiotic Laboratories Inc. Biotesting Division was awarded a $71,740 firm fixed price purchase order by the Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences to assess the cytochrome P450 (CYP450) enzyme induction potential of two test articles. Performance will take place in Plainsboro Township, New Jersey from August 2023 through March 2024. The award is in response to a solicitation requesting evaluation of the test...
This $23,800.00 firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian federal agency, to the University of Kansas Center for Research Inc. on September 12, 2024. The contract is for preliminary solid dosage form development strategy of an ALDH1A1 inhibitor drug candidate for NCATS' Extramural Research and Training Branch (ETB). This contract does not have a set-aside designation. The University of Kansas Center for Research...